Clinical Trial Update: Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial compares dosimetry-guided PRRT using Lu-177-DOTATOC to standard-dose PRRT in neuroendocrine neoplasm patients. The study is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• Lu-177-DOTATOC (Lutetium-177 DOTATOC)

Snippet

Sponsor: Tine Gregersen, MD | Conditions: Neuroendocrine Neoplasm | Phase 2 | Status: RECRUITING